** Shares of biopharma firm Ocular Therapeutix OCUL.O fall 13% to $6.21
** Company posts quarterly revenue of $17.08 million compared with analysts' estimates of $17.20 million, according data compiled by LSEG
** Reports Q4 loss of 29 cents per share compared to analysts' estimates of 25 cents
** Company delays data from late-stage study testing its drug, axpaxli, to treat wet age-related macular degeneration (wet AMD) to Q1 2026 from Q4 2025 as the FDA allows changes to study design through Special Protocol Agreement $(SPA.UK)$
** Wet AMD is a condition where abnormal blood vessels grow under the retina, leading to vision loss
** OCUL has fallen 28.2% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.